• Tango Therapeutics, Inc. reported past first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue following the end of its Gilead partnership research term, and the resignations of board members Alexis Borisy and Kanishka Pothula on May 13, 2026.
• Despite the wider loss and board changes, Tango highlighted US$379.80 million in cash expected to fund operations into 2028 and continued progress in its precision oncology pipeline, including MTAP-deleted selective PRMT5 inhibitor programs.
• Next, we will examine how the loss of Gilead collaboration revenue and wider quarterly loss shape Tango Therapeutics’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Tango Therapeutics' Investment Narrative?

To own Tango Therapeutics, you really have to believe that its precision oncology pipeline, especially the MTAP-deleted selective PRMT5 programs and vopimetostat combinations, can eventually justify years of heavy spending without near-term profitability. The latest quarter underlines that trade-off: Gilead collaboration revenue has disappeared, the net loss widened to US$45.51 million, and the stock dropped almost 20% in a single day, yet management points to roughly US$379.80 million in cash that could fund operations into 2028. That cash runway keeps the key 2026 data readouts and the new Erasca combination trial intact as the main short term catalysts, but it also sharpens the risk if those studies disappoint, since there is no longer a big pharma partner cushioning the blow. The recent board resignations add a governance wrinkle, although they do not appear to change the clinical priorities.

However, one risk stands out that shareholders should not overlook: reliance on unproven trials. Upon reviewing our latest valuation report, Tango Therapeutics' share price might be too optimistic.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value estimates for Tango span from US$10.00 to US$32.78, underscoring how far apart individual views can be. Set that against the recent loss of Gilead revenue and a wider quarterly loss, and you quickly see why opinions on Tango’s path from high revenue growth forecasts to eventual profitability are so divided.

Explore 2 other fair value estimates on Tango Therapeutics - why the stock might be worth as much as 59% more than the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tango Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Tango Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tango Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.